Gastric Disease

Cellvizio® is the real-time in vivo cellular imaging platform that is an adjunct to the standard of care and allows you to monitor the progression of Gastric Intestinal Metaplasia over time.

In 2018, 1 million new cases of gastric cancer were diagnosed¹ with a 5 year survival rate of 31%.²

Given these statistics, it is now the 3rd most common cause of cancer related deaths.¹ In cases where gastric cancer progresses more slowly over time, Cellvizio enables you to detect and monitor cellular changes in vivo using proprietary advanced imaging technology.

Cellvizio® Clinical Value

“CLE is trustworthy to make on-the-spot decisions on the diagnosis of early gastric cancer, the strategy of endoscopic treatment and follow-up"

-- Prof. Yanqing Li, Qilu Hospital Shandong University

Patient Management

Cellvizio mucosal assessment
using Cellvizio® GastroFlex^TM UHD Miniprobe 

1. World Health Organization: International Agency for Research on cancer, 2018, http://gco.iarc.fr/today/online-analysis-table?v=2018&mode=cancer&mode_population=continents&population=900&populations=900&key=asr&sex=0&cancer=39&type=
1&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=5&group_
cancer=1&include_nmsc=1&include_nmsc_other=1  
2. Harada et al. Recent trend in gastric cancer treatment in the USA, Journal of Cancer Metastasis and Treatment, 2018. 
3. Li Zhen et al. Confocal laser endomicroscopy for in vivo detection of gastric intestinal metaplasia: a randomized controlled trial, Endoscopy, 2013  
4. Bok G.H. et al. The Accuracy of probe-based Confocal Endomicroscopy versus Conventional Endoscopic Biopsies for the Diagnosis of Superficial Neoplasia (with videos). Gastro-Intestinal Endoscopy, 2013. 
5. Ji R, Zuo XL, Li CQ, Zhou CJ, Li YQ. Confocal endomicroscopy for in vivo prediction of completeness after endoscopic mucosal resection. Surg Endosc 2011; 25: 1933-1938
6. Jeon SR, Cho WY, Jin SY, Cheon YK, Choi SR, Cho JY. Optical biopsies by confocal endomicroscopy prevent additive endoscopic biopsies before endoscopic submucosal dissection in gastric epithelial neoplasias: a prospective, comparative study. Gastrointest Endosc 2011; 74: 772-780    

Cellvizio^® I.V.E. with Confocal Miniprobes™ are regulated Medical Devices, CE marked (CE 0459) (Class IIa - NB : G-MED) and FDA cleared. Cellvizio^® is a registered trademark and Confocal Miniprobe™ is a trademark of Mauna Kea Technologies. Cellvizio^® I.V.E. with Confocal Miniprobes™ is a confocal laser system with fiber optic probes that are intended to allow imaging of the internal microstructure of tissues including, but not limited to, the identification of cells and vessels and their organization or architecture. Once connected to the Cellvizio^® I.V.E.: The GastroFlex™ UHD and ColoFlex™ UHD Confocal Miniprobes™ are intended to allow imaging of anatomical tracts, i.e., gastrointestinal systems, accessed by an endoscope or endoscopic accessories. Please consult labels and instructions for use. These statements and the associated reference to specific clinical studies, are not intended to represent claims of safety or effectiveness for detecting or treating any specific condition or disease state. Rather this information is intended to provide useful reference to selected published literature describing physician experiences with the associated clinical uses. Any diagnostic assessment should always be made by the attending physician, based on the evaluation of all sources of clinical, endoscopic and other relevant information. These statements have not been reviewed, cleared, or approved by the U.S. FDA. The use of this medical device is exclusively reserved for health professionals. Product availability cannot be guaranteed in all countries. For further information, please contact your local sales representative.